NASDAQ · Medical - Devices

Neuropace, Inc. (NPCE) Stock

$12.67 +2.26% NASDAQ: NPCE Healthcare

Valuation

MetricValue
Price$12.67
Market Cap$431.97M
P/E Ratio-22.21
P/B Ratio36.45
P/S Ratio4.38
EPS (TTM)$-0.66
52-Week High$19.60
52-Week Low$9.22
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-119.68%
ROA-19.71%
ROCE-18.95%
Gross Margin-16.00%
Operating Margin-16.00%
Net Margin-19.34%
Debt/Equity5.88
Current Ratio5.22

Annual Financials (USD)

Metric20212022202320242025
Revenue$45.0M$46.0M$65.0M$80.0M$100.0M
Operating Profit$-24.0M$-41.0M$-27.0M$-22.0M$-16.0M
Net Profit$-36.0M$-47.0M$-33.0M$-27.0M$-21.0M
EPS$-2.17$-1.91$-1.27$-0.93$-0.66
Op Margin-52.5%-89.6%-41.5%-27.1%-16.3%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$134.0M$114.0M$108.0M$95.0M$106.0M
Total Liabilities$60.0M$79.0M$87.0M$87.0M$87.0M
Cash$19.0M$7.0M$18.0M$13.0M$22.0M
Borrowings$50.0M$70.0M$72.0M$73.0M$71.0M

Latest News

Here's Why You Should Retain NeuroPace Stock in Your Portfolio for Now Zacks · Jul 15, 2026 NeuroPace, Inc. (NPCE) Reveals FDA Approval of ECoG Assistant™ Insider Monkey · Jun 27, 2026 Wall Street Analysts Believe NeuroPace (NPCE) Could Rally 27.88%: Here's is How to Trade Zacks · Jun 15, 2026 NeuroPace (NPCE) Down 0.6% Since Last Earnings Report: Can It Rebound? Zacks · Jun 11, 2026 Here's Why You Should Add NeuroPace Stock to Your Portfolio Now Zacks · Jun 10, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-25.0M$-37.0M$-20.0M$-18.0M$-11.0M
Investing Cash Flow$-86.0M$23.0M$23.0M$9.0M$-1.0M
Financing Cash Flow$-2.0M$0$0$1.0M$-50.0M
Net Cash Flow$-7.0M$-13.0M$11.0M$-5.0M$8.0M
Free Cash Flow$-25.0M$-37.0M$-20.0M$-18.0M$-11.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.54
EV / EBITDA-39.91
FCF Yield-2.68%
Quick Ratio3.91
Interest Coverage-2.39
Return 1Y54.53%
Return 3Y253.73%
Return 5Y-35.32%

Ownership

Insiders Held4.04%
Institutions Held96.28%
Institutions Float Held100.33%
Institutional HolderSharesReport Date
Polar Capital Holdings PLC3,298,1042026-03-31
Soleus Capital Management, L.P.2,932,2072026-03-31
Morgan Stanley2,566,8392026-03-31
First Light Asset Management, LLC2,459,9662026-03-31
Blackrock Inc.2,346,3332026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
CVRXCVRx, Inc. $1.58 -5.95% -0.78 $41.93M 0.00%
MOBIMobia Medical, Inc. Common Stock $8.63 +0.82% -5.26 $286.94M 0.00%

About Neuropace, Inc.

Neuropace, Inc. is led by CEO Joel D. Becker, employs 184 people, headquartered in US, publicly traded since 2021.

Neuropace, Inc. (NPCE) stock trades at $12.67 with a market capitalization of $431.97M. The stock is valued at a price-to-earnings (P/E) ratio of -22.21, price-to-book of 36.45, price-to-sales of 4.38. Over the past 52 weeks the stock has ranged between $9.22 and $19.60, and currently trades 35.4% below its 52-week high.

On profitability, Neuropace, Inc. generates a return on equity (ROE) of -119.68%, return on capital employed of -18.95%, an operating margin of -16.00%, a net profit margin of -19.34%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides